SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Discontinues Experimental Blood Cancer Drug Program

Merck said it would stop developing an experimental drug for certain blood cancers after a review suggested its benefits may not outweigh its risks.

MRK

Related stories